Interferon use in solid tumors.
John
W J
WJ
Lucille P. Markey Cancer Center, University of Kentucky, Lexington 40536, USA.
Foon
K A
KA
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000628:therapy; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D004067:Digestive System Neoplasms / Q000628:therapy; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D002955:Leucovorin / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D009367:Neoplasm Staging; D009369:Neoplasms / Q000628:therapy*; D016019:Survival Analysis; D017211:Treatment Failure
D000964:Antimetabolites, Antineoplastic; D007155:Immunologic Factors; D016898:Interferon-alpha; D002955:Leucovorin; D005472:Fluorouracil